Cressey & Company

In 1976, Bryan Cressey founded one of America's first Private Equity firms, Golder Thoma Cressey Rauner, with three entrepreneurial friends. The firm was born.
Cressey & Company
Strategy
Buyout
sectors
Healthcare
-
geographies
North America
-
In the selection universe
In the vintage(s)

Key figures for Cressey & Company

1976
year established
3 billion
in assets under management
2
offices worldwide
+45
people
Data at
4/10/2024
Source: Public data from company websites and social networks. For the most up-to-date information, we invite our investors to consult the reports available in their own space.

About Cressey & Company

Originally a generalist company, Cressey & Company has gradually split into sector-specific specialist entities such as Thoma Bravo, the undisputed US technology leader, and Cressey & Company, a major player in the US healthcare sector.

Independent since 2008 and headed by its founder, Bryan Cressey, the firm now has 46 professionals, including 21 dedicated to investments and five to operations, spread across its two US offices, in Chicago and Nashville.

The company is wholly owned by its partners and has around $3bn under management.

What sets Cressey & Company apart

A pioneer in healthcare investment

The team is renowned for its specialisation in the exclusive healthcare sector , and over a very long period. Very few players of comparable size have made as many deals in the targeted segment.

It capitalises on its extensive experience to invest in niche healthcare markets, where it is an undisputed expert in complex deals, special regulatory issues, specific reimbursement aspects, etc.

It relies on a network of outstanding experts in the US healthcare ecosystem (both in-house and external, renowned specialists in the private and public sectors with in-depth knowledge of our businesses, best practices, current regulations and risks).

A unique investment strategy in a vast ecosystem

  • Cressey & Co specialises in investing in service providers,focusing on the growth and resilience of a $3Trn market, particularly in the context of an aging population and ongoing advances in medical technology,
  • However, the firm excludes biosciences, med-techs and suppliers of diagnostic solutions from their investment portfolio,
  • The firm's teams carry out in-depth, proactive analyses to identify the most promising sectors, includingfood for the elderly, ambulatory care, mobility support, home care, etc.
Views expressed herein represent the current opinion of Altaroc's investment Team. These views and opinions may change at any point in time without prior notification.

Disciplined operating procedures and stable returns

An analysis of the company's track record shows excellent performance and very low volatility of returns on investment since inception and across several economic cycles, which is rare among competitors in the healthcare sector.

Due diligence is carried out in-house through the teams' in-depth expertise, and transformation plans are laid out around proven roadmaps:  

- Leading of high-volume transformative acquisitions (M&A),

- Expanding geographical coverage based on regional successes,

- Improved operational performance through team commitment in finance, HR, and sales & marketing.

Views expressed herein represent the current opinion of Altaroc's investment Team. These views and opinions may change at any point in time without prior notification.

Transformation plans laid out around proven roadmaps

The firm follows proven roadmaps to help the companies in which it invests create value:

  • Leading high-volume transformative acquisitions (M&A),
  • Expanding geographical coverage based on regional successes,
  • Improved operational performance thanks to the commitment of the company's operating partners in finance, hR, and sales & marketing.
Views expressed herein represent the current opinion of Altaroc's investment Team. These views and opinions may change at any point in time without prior notification.
Views expressed herein represent the current opinion of Altaroc's investment Team. These views and opinions may change at any point in time without prior notification.

Focus on Cressey & Company funds

Cressey fund VII

Fund(s) selected
Fund(s) under selection
geographies
North America
target sectors
Healthcare
Diversification
Around 10 investments
Enterprise value
Between 500 M$ and 2 Mds$
Investment ticket
Between 50 M$ and 250 M$
Role
Majority or controlling positions
geographies
North America
target sectors
Healthcare
Diversification
Around 10 investments
Enterprise value
Between 500 M$ and 2 Mds$
Investment ticket
Between 50 M$ and 250 M$
Role
Majority or controlling positions

Cressey & Company manager news

Manager's videos
No items found.
Discover our exclusive services
No items found.
No items found.
Odyssey 2022
North America
Healthcare